Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Erratum to: A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting – rationale, design and baseline characteristics

  • Caroline Laurence1Email author,
  • Angela Gialamas1,
  • Lisa Yelland2,
  • Tanya Bubner1,
  • Philip Ryan2,
  • Kristyn Willson2,
  • Briony Glastonbury3,
  • Janice Gill4,
  • Mark Shephard5,
  • Justin Beilby6 and
  • for members of the PoCT Trial Management Committee
Trials200910:7

DOI: 10.1186/1745-6215-10-7

Received: 16 January 2009

Accepted: 28 January 2009

Published: 28 January 2009

The original article was published in Trials 2008 9:50

Following the publication of our article [1] we noticed an error within Additional file 2: Comparison of patient baseline characteristics by condition. The column headings 'Control' and 'Intervention' are incorrectly positioned in the table and should be switched.

The table should therefore appear as shown in Table 1 in this correction.
Table 1

Comparison of patient baseline characteristics by condition

Condition Group

Characteristic

 

Control n (%)

Intervention n (%)

Total n (%)

Diabetes

  

N = 785

N = 1182

N = 1967

 

Male

 

432 (55.0)

651 (55.1)

1083 (55.1)

 

Age (years)

Median (IQ range)

67.0 (59.0–74.0)

66.0 (58.0–73.0)

66.0 (59.0–73.0)

 

Aboriginal and Torres Strait Islander

Yes

4 (0.5)

23 (1.9)

27 (1.4)

  

No

723 (92.1)

1036 (87.6)

1759 (89.4)

  

Missing

58 (7.4)

123 (10.4)

181 (9.2)

 

BMI

Underweight

5 (0.6)

3 (0.3)

8 (0.4)

  

Normal

121 (15.4)

181 (15.3)

302 (15.4)

  

Overweight

243 (31.0)

386 (32.7)

629 (32.0)

  

Obese

334 (42.5)

464 (39.3)

798 (40.6)

  

Missing

82 (10.4)

148 (12.5)

230 (11.7)

 

HbA1c %

Median (IQ range)

7.1 (6.3–8.0)

6.9 (6.2–7.7)

7.0 (6.3–7.8)

  

Missing

64 (8.2)

90 (7.6)

154 (7.8)

 

Diabetes management:

    
 

Dietary control

Yes

446 (56.8)

604 (51.1)

1050 (53.4)

  

No

309 (39.4)

503 (42.6)

812 (41.3)

  

Missing

30 (3.8)

75 (6.3)

105 (5.3)

 

Insulin

Yes

145 (18.5)

204 (17.3)

349 (17.7)

  

No

610 (77.7)

903 (76.4)

1513 (76.9)

  

Missing

30 (3.8)

75 (6.3)

105 (5.3)

 

Prescription tablets

Yes

541 (68.9)

729 (61.7)

1270 (64.6)

  

No

214 (27.3)

378 (32.0)

592 (30.1)

  

Missing

30 (3.8)

75 (6.3)

105 (5.3)

 

Years since first diagnosed

< 1 year

39 (5.0)

67 (5.7)

106 (5.4)

  

1–5 years

256 (32.6)

403 (34.1)

659 (33.5)

  

6–10 years

201 (25.6)

235 (19.9)

436 (22.2)

  

> 10 years

230 (29.3)

311 (26.3)

541 (27.5)

  

Missing

59 (7.5)

166 (14.0)

225 (11.4)

Hyperlipidaemia

  

N = 1463

N = 2356

N = 3819

 

Male

 

753 (51.5)

1277 (54.2)

2030 (53.2)

 

Age (years)

Median (IQ range)

68.0 (60.0–74.0)

66.0 (58.0–74.0)

66.0 (59.0–74.0)

 

Aboriginal and Torres Strait Islander

Yes

9 (0.6)

26 (1.1)

35 (0.9)

  

No

1342 (91.7)

2102 (89.2)

3444 (90.2)

  

Missing

112 (7.7)

228 (9.7)

340 (8.9)

 

Index of Relative Socio-Economic Disadvantage

1st quartile

251 (17.2)

575 (24.4)

826 (21.6)

  

2nd quartile

476 (32.5)

756 (32.1)

1232 (32.3)

  

3rd quartile

390 (26.7)

663 (28.1)

1053 (27.6)

  

4th quartile

346 (23.7)

362 (15.4)

708 (18.5)

 

Co-morbid conditions:

    
 

Known heart disease

Yes

540 (36.9)

812 (34.5)

1352 (35.4)

  

No

869 (59.4)

1398 (59.3)

2267 (59.4)

  

Missing

54 (3.7)

146 (6.2)

200 (5.2)

 

Diabetes

 

509 (34.8)

853 (36.2)

1362 (35.7)

 

Smoking status

Current

103 (7.0)

201 (8.5)

304 (8.0)

  

Ex-smoker

644 (44.0)

1001 (42.5)

1645 (43.1)

  

Never smoked

654 (44.7)

990 (42.0)

1644 (43.0)

  

Missing

62 (4.2)

164 (7.0)

226 (5.9)

 

Total cholesterol

Median (IQ range)

4.7 (4.0–5.4)

4.6 (4.0–5.4)

4.7 (4.0–5.4)

  

Missing

99 (6.8)

186 (7.9)

285 (7.5)

 

Triglyceride

Median (IQ range)

1.6 (1.1–2.2)

1.6 (1.2–2.2)

1.6 (1.2–2.2)

  

Missing

185 (12.6)

204 (8.7)

389 (10.2)

 

HDL-C

Median (IQ range)

1.3 (1.1–1.6)

1.3 (1.1–1.5)

1.3 (1.1–1.6)

  

Missing

239 (16.3)

515 (21.9)

754 (19.7)

Anticoagulant therapy

  

N = 372

N = 572

N = 944

 

Male

 

217 (58.3)

326 (57.0)

543 (57.5)

 

Age (years)

Median (IQ range)

73.0 (66.0–79.0)

73.0 (65.0–78.0)

73.0 (65.0–79.0)

 

BMI

Underweight

7 (1.9)

5 (0.9)

12 (1.3)

  

Normal

90 (24.2)

165 (28.8)

255 (27.0)

  

Overweight

130 (34.9)

190 (33.2)

320 (33.9)

  

Obese

111 (29.8)

132 (23.1)

243 (25.7)

  

Missing

34 (9.1)

80 (14.0)

114 (12.1)

 

Multiple co-morbidities

Yes

170 (45.7)

285 (49.8)

455 (48.2)

  

No

186 (50.0)

259 (45.3)

445 (47.1)

  

Missing

16 (4.3)

28 (4.9)

44 (4.7)

 

INR

Below target range

73 (19.6)

115 (20.1)

188 (19.9)

  

Within target range

197 (53.0)

316 (55.2)

513 (54.3)

  

Above target range

37 (9.9)

63 (11.0)

100 (10.6)

  

Missing

65 (17.5)

78 (13.6)

143 (15.1)

Notes

Authors’ Affiliations

(1)
Discipline of General Practice, The University of Adelaide
(2)
Discipline of Public Health, The University of Adelaide
(3)
Save Sight Institute, University of Sydney
(4)
RCPA Quality Assurance Programs Pty Ltd
(5)
Community Point-of-Care Services, Flinders University Rural Clinical School, Flinders University
(6)
Faculty of Health Sciences, The University of Adelaide

References

  1. Laurence C, Gialamas A, Yelland L, Bubner T, Ryan P, Willson K, Glastonbury B, Gill J, Shepard M, Beilby J, for members of the PoCT Trial Management Committee: A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting – rationale, design and baseline characteristics. Trials. 2008, 9: 50-10.1186/1745-6215-9-50.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Laurence et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement